BCMA-targeted therapies for multiple myeloma: latest updates from 2024 ASH annual meeting

Abstract B-cell maturation antigen (BCMA) is currently the most extensively explored target for multiple myeloma (MM). BCMA-targeted therapies such as antibody-drug conjugate (ADC), bispecific antibodies (BsAbs), chimeric antigen receptor T(CAR-T) cell have shown promising therapeutic prospects in M...

Full description

Saved in:
Bibliographic Details
Main Authors: Huijian Zheng, Huajian Xian, Wenjie Zhang, Chaoqun Lu, Renyao Pan, Han Liu, Zhenshu Xu
Format: Article
Language:English
Published: BMC 2025-03-01
Series:Journal of Hematology & Oncology
Subjects:
Online Access:https://doi.org/10.1186/s13045-025-01675-5
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items